Filing Flows › Comparisons › PCRX vs LQDA
Pacira BioSciences vs Liquidia: PCRX and LQDA compared
Pacira BioSciences is the larger company: $177M of revenue in its latest quarter (Q3 2026) against $172M for Liquidia (Q2 2026). Liquidia is growing faster (19× against -2% a year earlier). Liquidia is more profitable, with an operating margin of 49.8% against 12.6%.
Where the money goes: PCRX and LQDA
Pacira BioSciences (PCRX) · Q3 2026
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
Liquidia (LQDA) · Q2 2026
Liquidia, Q2 2026: revenue $172M (19× year over year), operating margin 49.8%, net earnings $74.7M, operating cash flow $80.2M. The chart follows the revenue to costs, profit and cash.
| Pacira BioSciences (PCRX) | Liquidia (LQDA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $177M | $172M |
| Revenue growth, Y/Y | -2% | 19× |
| Operating margin | 12.6% | 49.8% |
| Net earnings | $28.5M | $74.7M |
| Net margin | 16.1% | 43.5% |
| Operating cash flow | $50.1M | $80.2M |
| Free cash flow | $46.4M | $69.0M |
| Market value | $1.5B | — |
| P/E | 100.3× | — |
| Analysts’ mean target | $33.57 | — |
Where the revenue comes from
Pacira BioSciences
- Net product sales: $175M (99%)
- Bupivacaine liposome injectable suspension: $1.2M (1%)
Liquidia
- Product sales, net: $170M (99%)
- Service revenue, net: $1.3M (1%)
Questions
Which is bigger, Pacira BioSciences or Liquidia?
Pacira BioSciences is the larger company: $177M of revenue in its latest quarter (Q3 2026) against $172M for Liquidia (Q2 2026).
Is Pacira BioSciences or Liquidia growing faster?
Liquidia is growing faster (19× against -2% a year earlier).
Which is more profitable, Pacira BioSciences or Liquidia?
Liquidia is more profitable, with an operating margin of 49.8% against 12.6%.
More: Pacira BioSciences earnings · how Pacira BioSciences makes money · Liquidia earnings · how Liquidia makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.